FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013116082> ?p ?o ?g. }

• W2013116082 endingPage "S155" @default.
• W2013116082 startingPage "S147" @default.
• W2013116082 abstract "In 1981, Imbach et al. (Lancet, 1, 1228-1231) reported that infusion of intravenous immunoglobulin (IVIG) would substantially elevate platelet counts in children with acute or chronic idiopathic thrombocytopenic purpura (ITP). Subsequent studies confirmed these findings and extended the effect to adults and to newborns with passive immune thrombocytopenia. Studies in children with acute ITP demonstrated that administration of IVIG was the fastest way to increase a patient's platelet count, and that this agent could be given at doses as high as 1 g/kg/day so that the course of therapy and response to treatment would be more rapid. Reports of effective treatment of patients with autoimmune neutropenia and autoimmune hemolytic anemia by IVIG broadened the scope of its usefulness. In addition, several studies in children and adults with chronic ITP suggested that repeated infusions were a safe and effective way to maintain an adequate platelet count in such patients, and might also gradually lead to lasting improvement. These studies and Imbach's controlled trial in children with acute ITP suggested that IVIG therapy might provide a curative effect in addition to the acute effect. To combine all of these clinical effects with a multitude of in vitro observations to explain the mechanism of action of IVIG is complicated. Fehr et al. (N. Engl. J. Med. 306, 1254-1258, 1982) showed that Fc receptor blockade occurs following administration of IVIG. This effect is clearly demonstrated in vivo by the delayed removal from the vascular space of antibody-coated red blood cells following infusion of IVIG. In addition, many less well-defined effects occur in relation to immunoglobulin production, induction of suppressor cells, antiplatelet antibody levels, and bone marrow platelet production. Studies continue to try to define which effects actually underlie the clinical effects seen, and which are merely test-tube phenomena." @default.
• W2013116082 created "2016-06-24" @default.
• W2013116082 creator A5062688748 @default.
• W2013116082 date "1989-11-01" @default.
• W2013116082 modified "2023-09-25" @default.
• W2013116082 title "The use of intravenous γ-globulin in idiopathic thrombocytopenic purpura" @default.
• W2013116082 cites W1647961178 @default.
• W2013116082 cites W1971957984 @default.
• W2013116082 cites W1979820418 @default.
• W2013116082 cites W1990977801 @default.
• W2013116082 cites W2001592943 @default.
• W2013116082 cites W2047983899 @default.
• W2013116082 cites W2048259741 @default.
• W2013116082 cites W2064525443 @default.
• W2013116082 cites W2113669085 @default.
• W2013116082 cites W2140903638 @default.
• W2013116082 cites W2288675092 @default.
• W2013116082 cites W2341400992 @default.
• W2013116082 cites W2398313758 @default.
• W2013116082 cites W2463027284 @default.
• W2013116082 cites W4299587195 @default.
• W2013116082 doi "https://doi.org/10.1016/0090-1229(89)90080-9" @default.
• W2013116082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2477185" @default.
• W2013116082 hasPublicationYear "1989" @default.
• W2013116082 type Work @default.
• W2013116082 sameAs 2013116082 @default.
• W2013116082 citedByCount "33" @default.
• W2013116082 countsByYear W20131160822012 @default.
• W2013116082 countsByYear W20131160822013 @default.
• W2013116082 countsByYear W20131160822014 @default.
• W2013116082 countsByYear W20131160822017 @default.
• W2013116082 countsByYear W20131160822018 @default.
• W2013116082 countsByYear W20131160822019 @default.
• W2013116082 countsByYear W20131160822022 @default.
• W2013116082 crossrefType "journal-article" @default.
• W2013116082 hasAuthorship W2013116082A5062688748 @default.
• W2013116082 hasConcept C126322002 @default.
• W2013116082 hasConcept C159654299 @default.
• W2013116082 hasConcept C203014093 @default.
• W2013116082 hasConcept C2776694085 @default.
• W2013116082 hasConcept C2777063308 @default.
• W2013116082 hasConcept C2779771385 @default.
• W2013116082 hasConcept C71924100 @default.
• W2013116082 hasConcept C8891405 @default.
• W2013116082 hasConcept C89560881 @default.
• W2013116082 hasConceptScore W2013116082C126322002 @default.
• W2013116082 hasConceptScore W2013116082C159654299 @default.
• W2013116082 hasConceptScore W2013116082C203014093 @default.
• W2013116082 hasConceptScore W2013116082C2776694085 @default.
• W2013116082 hasConceptScore W2013116082C2777063308 @default.
• W2013116082 hasConceptScore W2013116082C2779771385 @default.
• W2013116082 hasConceptScore W2013116082C71924100 @default.
• W2013116082 hasConceptScore W2013116082C8891405 @default.
• W2013116082 hasConceptScore W2013116082C89560881 @default.
• W2013116082 hasIssue "2" @default.
• W2013116082 hasLocation W20131160821 @default.
• W2013116082 hasLocation W20131160822 @default.
• W2013116082 hasOpenAccess W2013116082 @default.
• W2013116082 hasPrimaryLocation W20131160821 @default.
• W2013116082 hasRelatedWork W1970346249 @default.
• W2013116082 hasRelatedWork W1981783160 @default.
• W2013116082 hasRelatedWork W2007104080 @default.
• W2013116082 hasRelatedWork W2103974498 @default.
• W2013116082 hasRelatedWork W2108472544 @default.
• W2013116082 hasRelatedWork W2148345396 @default.
• W2013116082 hasRelatedWork W2409724498 @default.
• W2013116082 hasRelatedWork W2411389867 @default.
• W2013116082 hasRelatedWork W3031438654 @default.
• W2013116082 hasRelatedWork W32392874 @default.
• W2013116082 hasVolume "53" @default.
• W2013116082 isParatext "false" @default.
• W2013116082 isRetracted "false" @default.
• W2013116082 magId "2013116082" @default.
• W2013116082 workType "article" @default.